{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:38:37Z","timestamp":1793234317254,"version":"4.5.0"},"reference-count":18,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Chronic lymphocytic leukemia (CLL) displays substantial clinical heterogeneity, yet access to genomic prognostic testing remains limited in many real-world and resource-constrained settings. Readily available biomarkers that reflect disease biology are therefore clinically valuable. Serum albumin, an inexpensive marker associated with systemic inflammation and tumor burden, has shown emerging prognostic potential. This study evaluated the impact of baseline albumin on time to first treatment (TTFT) and overall survival (OS) in CLL. Methods: We retrospectively analyzed adult patients with confirmed CLL treated at a single tertiary center. Baseline demographic, clinical, and laboratory features were recorded, and serum albumin was dichotomized at 4 g\/dL. TTFT and OS were estimated using the Kaplan\u2013Meier methodology. Variables with p &lt; 0.1 in univariate analyses were included in multivariate Cox regression models. Results: A total of 230 patients were included. The median age at diagnosis was 62.5 years; 52.2% were male, and 14.8% had serum albumin &lt;4 g\/dL. Low albumin was associated with older age, advanced Rai\/Binet stage, anemia, higher lymphocyte counts, and greater treatment requirement (all p &lt; 0.05). Median follow-up was 20 months (range, 1\u2013288). Patients with albumin &lt;4 g\/dL had inferior 5-year OS (78.4% vs. 98.7%). Although serum albumin correlated with both TTFT and OS in univariate analyses, it did not remain independently significant in multivariate models. Conclusions: While not independently prognostic, baseline serum albumin is strongly linked to adverse clinical features and poorer unadjusted survival. As a readily available, low-cost parameter, albumin may offer practical value for early risk stratification\u2014particularly in regions where routine molecular testing is constrained.<\/jats:p>","DOI":"10.3390\/jcm15031315","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T08:15:54Z","timestamp":1770624954000},"page":"1315","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic Impact of Serum Albumin Levels at Diagnosis in Patients with Chronic Lymphocytic Leukemia"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8742-3388","authenticated-orcid":false,"given":"Selin","family":"K\u00fc\u00e7\u00fckyurt Kaya","sequence":"first","affiliation":[{"name":"Department of Hematology, Ankara Etlik City Hospital, 06170 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-7604","authenticated-orcid":false,"given":"Hacer Berna","family":"Afacan \u00d6zt\u00fcrk","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Etlik City Hospital, 06170 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1239-3246","authenticated-orcid":false,"given":"Oguzhan","family":"Koca","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, \u0130stanbul University-Cerrahpa\u015fa, 34098 \u0130stanbul, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1539-077X","authenticated-orcid":false,"given":"Lale","family":"Ayd\u0131n Kaynar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Etlik City Hospital, 06170 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2094-6455","authenticated-orcid":false,"given":"Ufuk","family":"G\u00f6rd\u00fck","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Etlik City Hospital, 06170 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9108-876X","authenticated-orcid":false,"given":"Asena","family":"Dikyar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Etlik City Hospital, 06170 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4391-1387","authenticated-orcid":false,"given":"Haktan Ba\u011f\u0131\u015f","family":"Erdem","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Ankara Etlik City Hospital, 06170 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8835-2689","authenticated-orcid":false,"given":"Kadir","family":"Acar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Etlik City Hospital, 06170 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2375-1117","authenticated-orcid":false,"given":"Murat","family":"Albayrak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Etlik City Hospital, 06170 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-8342","authenticated-orcid":false,"given":"Ahmet K\u00fcr\u015fad","family":"G\u00fcne\u015f","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ankara Etlik City Hospital, 06170 Ankara, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101098","DOI":"10.1016\/j.tranon.2021.101098","article-title":"New kid on the block: C-reactive protein-to-albumin ratio as a new prognostic marker for chronic lymphocytic leukemia: Comment on \u201cC-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases\u201d","volume":"14","author":"Bahar","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa2310063","article-title":"Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease","volume":"390","author":"Munir","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"International CLL-IPI Working Group (2016). An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol., 17, 779\u2013790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000533704","article-title":"Prognostic Markers in the Era of Targeted Therapies","volume":"147","author":"Kang","year":"2024","journal-title":"Acta Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.ijbiomac.2021.06.140","article-title":"Serum albumin levels and inflammation","volume":"184","author":"Sheinenzon","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tang, Q., Li, X., and Sun, C.R. (2024). Predictive value of serum albumin levels on cancer survival: A prospective cohort study. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1323192"},{"key":"ref_10","first-page":"113","article-title":"Prognostic significance of serum albumin in chronic lymphocytic leukemia","volume":"76","author":"Levis","year":"1991","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"101035","DOI":"10.1016\/j.tranon.2021.101035","article-title":"C-reactive protein-to-albumin ratio is an independent poor prognostic factor in newly diagnosed chronic lymphocytic leukaemia: A clinical analysis of 322 cases","volume":"14","author":"Tang","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-022-00756-9","article-title":"Chronic lymphocytic leukemia treatment algorithm 2022","volume":"12","author":"Hampel","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Mkhwanazi, Z.A., Nyambuya, T.M., Mfusi, S.A., and Nkambule, B.B. (2022). Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: A systematic review and meta-analysis of prognostic factors. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10223-0"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"664","DOI":"10.4143\/crt.2018.358","article-title":"Albumin-to-Fibrinogen Ratio as an Independent Prognostic Parameter in Untreated Chronic Lymphocytic Leukemia: A Retrospective Study of 191 Cases","volume":"51","author":"Zou","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/s41375-020-0727-y","article-title":"Prognostic model for newly diagnosed CLL patients in Binet stage A: Results of the multicenter, prospective CLL1 trial of the German CLL study group","volume":"34","author":"Hoechstetter","year":"2020","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1315\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:15:50Z","timestamp":1770786950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/3\/1315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15031315"],"URL":"https:\/\/doi.org\/10.3390\/jcm15031315","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]}}}